A Phase 2b, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Oral Solabegron Immediate Release Tablets in the Treatment of Overactive Bladder (OAB) in Adult Female Subjects
Latest Information Update: 12 Feb 2019
At a glance
- Drugs Solabegron (Primary)
- Indications Overactive bladder
- Focus Therapeutic Use
- Sponsors Velicept Therapeutics
- 31 Jan 2019 Status changed from active, no longer recruiting to completed.
- 05 Nov 2018 Status changed from recruiting to active, no longer recruiting.
- 05 Mar 2012 New trial record